Search Results
Mar 10, 2026, 17:33 ET Bota Launches SAION AI -- Physical AI Platform for Biomanufacturing
publications and patents, and public biological databases. Combined with leading AI4Science models, SAION AI develops multi-scale understanding across the gene–protein–cell–fermentation continuum, enabling systematic design and data-driven scientific decisions.Orchestration: Intelligent Research CoordinationThe
More news about: Bota
Mar 10, 2026, 10:13 ET Tsingke Biotech and iGeneTech Forge Strategic Partnership to Lead Synthetic Biology Advancements
laboratory production (2nmol) to large-scale industrial synthesis (12mmol). Their gene synthesis services include:Primer Synthesis (<300nt)Gene Synthesis (300bp–5kb)Long Gene Synthesis (>5kb)On the other hand, iGeneTech contributes its proprietary
More news about: Beijing Tsingke Biotech Co., Ltd.
Mar 10, 2026, 10:13 ET Tsingke Biotech and iGeneTech Forge Strategic Partnership to Lead Synthetic Biology Advancements
laboratory production (2nmol) to large-scale industrial synthesis (12mmol). Their gene synthesis services include:Primer Synthesis (<300nt)Gene Synthesis (300bp–5kb)Long Gene Synthesis (>5kb)On the other hand, iGeneTech contributes its proprietary
More news about: Beijing Tsingke Biotech Co., Ltd.
Mar 10, 2026, 10:00 ET Multi-Organization Partnership Announces $2.5 Million for Aging & Cancer Research
Foundation is a pioneer in cancer research and its mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer and develops minimally toxic treatments for patients. Through the Foundation's collaborative group of world-class scientists,
More news about: The Mark Foundation for Cancer Research
Mar 10, 2026, 09:00 ET TRIANGLE INSIGHTS GROUP BY VALERIS ANNOUNCES APPOINTMENT OF ERIN SOLANO TO PARTNER
local level to the global stage. She has launched products in diverse therapy areas including vaccines, rare disease, respiratory, oncology, cell and gene therapy, cardiovascular, metabolic, and immunology, with further expertise in issues around biosimilars, value-based contracting, and a changing healthcare
More news about: Valeris
Mar 10, 2026, 09:00 ET Investors who lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class Action - RGNX
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm
Mar 10, 2026, 08:37 ET QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class Action - Hagens Berman
said in a call with reporters Thursday that the data from the testing of Uniqure's gene therapy were flawed and signaled the drug candidate didn't meet the bar for agency approval." The therapy at issue is uniQure's lead gene therapy candidate, AMT-130, which is being developed to slow the progression of
More news about: Hagens Berman Sobol Shapiro LLP
Mar 10, 2026, 08:32 ET The American Diabetes Association Announces the 2026 National Scientific and Health Care Achievement Award Winners
Kadowaki's seminal contributions have been in the biology and genetics of insulin action and resistance. From discovery of the first insulin receptor gene mutations in patients with extreme insulin resistance to creation of the first mouse model of targeted insulin action defects, his work has been key
More news about: American Diabetes Association
Mar 10, 2026, 08:03 ET Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis
Genomenon produced literature-derived real-world evidence by applying fit-for-purpose AI and expert review to curate and classify variants in the GLA gene. The resulting variant evidence has been made freely available to the global clinical and research community through the Mastermind Genomic Intelligence
More news about: Genomenon
Mar 10, 2026, 08:00 ET Andelyn Biosciences Establishes The Andelyn Foundation to Support Families Living with Rare and Ultra-Rare Diseases
alone.About Andelyn Biosciences, Inc.Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization, and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn's deep scientific expertise has resulted in
More news about: Andelyn Biosciences
Mar 10, 2026, 08:00 ET Chris Duke joins RBL LLC leadership team as Operating Partner
Duke, a seasoned biopharmaceutical executive and former CEO of Gennao Bio, brings extensive experience in rare diseases, gene therapy, global commercialization, and company building that will be instrumental in RBL's mission to accelerate lifesaving therapies from bench to
More news about: RBL LLC
Mar 10, 2026, 08:00 ET Origin Agritech Launches "Aoyun 2026" New Variety Promotion Program to Drive Commercialization of Next-Generation Seed Varieties
established heading into the 2026 selling season. Origin's research pipeline is stocked with competitive germplasm, and commercialization of GMO and gene-editing technologies is being accelerated through Origin's strategic alliance with China Golden-mark Biotech. During fiscal year 2025, Origin launched
More news about: Origin Agritech Limited
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including
More news about: ExCellThera
Mar 10, 2026, 07:02 ET Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including
More news about: ExCellThera
Mar 10, 2026, 07:00 ET Genprex to Participate at BIO Europe Spring 2026
collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a
More news about: Genprex, Inc.
Mar 10, 2026, 07:00 ET Zoetis expands Human-Animal Bond Certification scholarship to include veterinary technician students
of continuing education for veterinary professionals, NAVC continually looks for ways to elevate and grow our programming and content," said NAVC CEO Gene O'Neill. "The human-animal bond plays an integral role in the lives of pets, people and the veterinary team that cares for both. NAVC is proud to partner
More news about: North American Veterinary Community (NAVC)
Mar 10, 2026, 07:00 ET Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
muscular dystrophyBecker is a rare, genetic, X-linked neuromuscular disorder that predominantly affects males. Mutations in the dystrophin gene result in contraction-induced muscle damage, leading to progressive, irreversible muscle loss, motor function decline, and shortened lifespan. Symptoms
More news about: Edgewise Therapeutics
Mar 10, 2026, 05:59 ET EQT Foundation opens applications for science grants to overcome the blood-brain barrier and transform CNS drug delivery
permeabilizers, and genetically or pharmacologically induced transient BBB opening with spatiotemporal control and strong safety rationale CNS-targeted gene therapies and large molecule delivery: AAV capsid engineering, alternative viral vectors, non-viral systems such as lipid or polymeric nanoparticles,
More news about: EQT
Mar 10, 2026, 05:13 ET Gene Solutions, 2. Uluslararası Kalıtsal Kanserler Kongresi 2026'da Güçlü Gerçek Dünya Kanıtları ile Türkiye Pazarına Stratejik Girişini Duyurdu
https://genesolutions.com/news/gene-solutions-atc-introducing-oncology-portfolio-in-turkey-at-the-2nd-international-hereditary-cancers-congress-with-industry-symposium-oral-presentation/Türk Klinisyenlerden Güçlü İvmeGene Solutions TR-EEMEA-CIS Genel
More news about: Gene Solutions Genomics Pte Ltd
Mar 10, 2026, 03:33 ET The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard
production contaminant, trace endotoxin triggers immune responses, skews results, and jeopardizes patient safety—risks that are critical in immunology, cell/gene therapy, and vaccine production. Endotoxin-free proteins are therefore essential for experimental accuracy, safety, and regulatory compliance.The
More news about: Sino Biological, Inc.
Mar 10, 2026, 03:22 ET The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard
production contaminant, trace endotoxin triggers immune responses, skews results, and jeopardizes patient safety—risks that are critical in immunology, cell/gene therapy, and vaccine production. Endotoxin-free proteins are therefore essential for experimental accuracy, safety, and regulatory compliance.The
More news about: Sino Biological, Inc.
Mar 09, 2026, 17:31 ET Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
Prostate Cancer (NEPC) and Extra-pulmonary NEC (EP-NEC), and Large cell Neuroendocrine Lung Carcinoma (LCNEC). Several companies have advanced gene therapies into clinical trials, including Boehringer Ingelheim and Oxford BioTherapeutics (obrixtamig [BI 764532]), Merck and Daiichi Sankyo
More news about: DelveInsight Business Research, LLP
Mar 09, 2026, 16:23 ET Cell and Gene Therapy Manufacturing Market to Reach USD 146.2 Billion by 2032 Amid Rising Demand for Personalized Therapies, Viral Vector Capacity, and Automated Bioprocessing - Credence Research
platforms, increasing commercialization of gene and cell therapies, and continued innovation in automated, scalable, and quality-driven manufacturing processes across the biotechnology and pharmaceutical industries.Scope & Segmentation – Cell and Gene Therapy Manufacturing MarketThe
More news about: Credence Research Inc.
Mar 09, 2026, 11:01 ET Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 MDA Clinical & Scientific Conference
Brogidirsen is an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP as an investigational therapy for DMD patients with dystrophin gene mutations that are amenable to exon 44 skipping."We are thrilled to see the data continue to demonstrate long-term efficacy in DMD patients amenable
More news about: NS Pharma, Inc.
Mar 09, 2026, 10:01 ET Fibrinogen Concentrate Market to Reach $5.9 Billion, Globally, by 2033 at 6.1% CAGR: Allied Market Research
Analysis and Industry Forecast, 2023-2032Gene Expression Market: Global Opportunity Analysis and Industry Forecast, 2021-2031AVENUE - A Subscription-Based Library (Premium
More news about: Allied Market Research